MX2022009492A - Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante. - Google Patents

Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.

Info

Publication number
MX2022009492A
MX2022009492A MX2022009492A MX2022009492A MX2022009492A MX 2022009492 A MX2022009492 A MX 2022009492A MX 2022009492 A MX2022009492 A MX 2022009492A MX 2022009492 A MX2022009492 A MX 2022009492A MX 2022009492 A MX2022009492 A MX 2022009492A
Authority
MX
Mexico
Prior art keywords
von willebrand
menorrhagia
treatment
patients
administration
Prior art date
Application number
MX2022009492A
Other languages
English (en)
Inventor
Bettina Ploder
Françoise Truong-Berthoz
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2022009492A publication Critical patent/MX2022009492A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención hace referencia a un método para tratar la menorragia en un sujeto con enfermedad de von Willebrand (EVW) que comprende administrar una cantidad terapéutica de factor de von Willebrand recombinante (FVWr) al sujeto.
MX2022009492A 2020-02-04 2021-02-04 Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante. MX2022009492A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062969998P 2020-02-04 2020-02-04
PCT/US2021/016592 WO2021158777A1 (en) 2020-02-04 2021-02-04 Treatment of menorrhagia in patients with severe von willebrand disease by administration of recombinant vwf

Publications (1)

Publication Number Publication Date
MX2022009492A true MX2022009492A (es) 2022-11-09

Family

ID=74759563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009492A MX2022009492A (es) 2020-02-04 2021-02-04 Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.

Country Status (12)

Country Link
US (1) US20230398188A1 (es)
EP (1) EP4100048A1 (es)
JP (1) JP2023514541A (es)
KR (1) KR20220150303A (es)
CN (1) CN115335074A (es)
AR (1) AR121268A1 (es)
AU (1) AU2021216945A1 (es)
BR (1) BR112022015326A2 (es)
CA (1) CA3169996A1 (es)
MX (1) MX2022009492A (es)
TW (1) TW202134266A (es)
WO (1) WO2021158777A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
JPS62502589A (ja) 1985-04-11 1987-10-08 ザ・チヤイルドレンズ・メデイカル・センタ−・コ−ポレ−シヨン フオン・ビルブラント因子
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AT405485B (de) 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
US7884075B2 (en) 2004-12-27 2011-02-08 Baxter International Inc. Polymer-factor VIII-von Willebrand factor-conjugates
WO2007077217A2 (en) 2006-01-04 2007-07-12 Baxter International Inc. Oligopeptide-free cell culture media
KR101772674B1 (ko) 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 ｖｗｆ 제제
HUE038193T2 (hu) 2010-07-08 2018-09-28 Baxalta GmbH Eljárás rekombináns nagy molekulatömegû vWF elõállítására sejttenyészetben
EP3858375B1 (en) 2011-06-10 2024-03-20 Takeda Pharmaceutical Company Limited Treatment of coagulation disease by administration of recombinant vwf

Also Published As

Publication number Publication date
CA3169996A1 (en) 2021-08-12
EP4100048A1 (en) 2022-12-14
WO2021158777A1 (en) 2021-08-12
AU2021216945A1 (en) 2022-09-01
KR20220150303A (ko) 2022-11-10
TW202134266A (zh) 2021-09-16
US20230398188A1 (en) 2023-12-14
AR121268A1 (es) 2022-05-04
CN115335074A (zh) 2022-11-11
JP2023514541A (ja) 2023-04-06
BR112022015326A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
HRP20170056T2 (hr) Terapija male učestalosti glatiramer acetatom
PH12015502063A1 (en) Treatment of pediatric growth hormone deficiency with human growth hormone analogues
ES2193159T3 (es) Una formulacion de factor de coagulacion viii.
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
JP2016514132A5 (es)
JP2014516088A5 (es)
RU2014102924A (ru) Композиция для контролируемой стимуляции яичников
AR086904A1 (es) Tratamiento de trastornos de la coagulacion por medio de la administracion de factor recombinante de von willebrand (vwf)
BR112021009856A8 (pt) Terapia para tratamento do câncer com uma administração intratumoral e / ou intravenosa de um mva recombinante que codifica 4-1bbl (cd137l) e / ou cd40l
RU2014127298A (ru) Применения иммуноконъюгатов, мишенью которых является cd138
MX2022000430A (es) Administracion de agonista de sting e inhibidores de puntos de control.
MX2022009492A (es) Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de factor de von willebrand (fvw) recombinante.
CO2020001314A2 (es) Tratamiento de pacientes con enfermedad de von willebrand grave que se someten a cirugía electiva mediante administración de vwf recombinante
RU2016138790A (ru) Композиции на основе сиалированных гликопротеинов и их применение
CO2020001322A2 (es) Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
US11318148B2 (en) Preservative-free treprostinil devices
EA202000298A1 (ru) ПРОТИВОКОРОНАВИРУСНОЕ СРЕДСТВО ДЛЯ КОМБИНИРОВАННОЙ ТЕРАПИИ COVID-19 (SARS-CoV-2) И СПОСОБ ЛЕЧЕНИЯ
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
RU2013148539A (ru) Алиспоривир для лечения инфекции вируса гепатита с
JP2020526525A5 (es)
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
CO2021011340A2 (es) Métodos de tratamiento profiláctico con vwf recombinante (rvwf)
Anjum et al. A prospective randomized controlled trial comparing the effects of dexmedetomidine and fentanyl on attenuation of pressor response during laryngoscopy and intubation in neurosurgical patients
Yutskovskaya et al. Neck and chest: MesoCaHA for cheeks, neck, and décolletage